The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis.

Nicolino Ruperto, Angela Pistorio, Angelo Ravelli, Lisa G. Rider, Clarissa Pilkington, Sheila Oliveira, Nico Wulffraat, Graciela Espada, Stella Garay, Ruben Cuttica, Michael Hofer, Pierre Quartier, Jose Melo-Gomes, Ann M. Reed, Malgorzata Wierzbowska, Brian M. Feldman, Miroslav Harjacek, Hans Iko Huppertz, Susan Nielsen, Berit FlatoPekka Lahdenne, Harmut Michels, Kevin J. Murray, Lynn Punaro, Robert Rennebohm, Ricardo Russo, Zsolt Balogh, Madeleine Rooney, Lauren M. Pachman, Carol Wallace, Philip Hashkes, Daniel J. Lovell, Edward H. Giannini, Boel Andersson Gare, Alberto Martini, Rheumatology International Trials Organisation (PRINTO) Paediatric Rheumatology International Trials Organisation (PRINTO), Rheumatology Collaborative Study Group (PRCSG) Pediatric Rheumatology Collaborative Study Group (PRCSG)

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

To develop a provisional definition for the evaluation of response to therapy in juvenile dermatomyositis (DM) based on the Paediatric Rheumatology International Trials Organisation juvenile DM core set of variables. Thirty-seven experienced pediatric rheumatologists from 27 countries achieved consensus on 128 difficult patient profiles as clinically improved or not improved using a stepwise approach (patient's rating, statistical analysis, definition selection). Using the physicians' consensus ratings as the "gold standard measure," chi-square, sensitivity, specificity, false-positive and-negative rates, area under the receiver operating characteristic curve, and kappa agreement for candidate definitions of improvement were calculated. Definitions with kappa values >0.8 were multiplied by the face validity score to select the top definitions. The top definition of improvement was at least 20% improvement from baseline in 3 of 6 core set variables with no more than 1 of the remaining worsening by more than 30%, which cannot be muscle strength. The second-highest scoring definition was at least 20% improvement from baseline in 3 of 6 core set variables with no more than 2 of the remaining worsening by more than 25%, which cannot be muscle strength (definition P1 selected by the International Myositis Assessment and Clinical Studies group). The third is similar to the second with the maximum amount of worsening set to 30%. This indicates convergent validity of the process. We propose a provisional data-driven definition of improvement that reflects well the consensus rating of experienced clinicians, which incorporates clinically meaningful change in core set variables in a composite end point for the evaluation of global response to therapy in juvenile DM.

Original languageEnglish (US)
Pages (from-to)1533-1541
Number of pages9
JournalArthritis care & research
Volume62
Issue number11
StatePublished - Nov 2010
Externally publishedYes

Fingerprint

Rheumatology
Muscle Strength
Pediatrics
Myositis
Reproducibility of Results
ROC Curve
Therapeutics
Physicians
Sensitivity and Specificity
Juvenile dermatomyositis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ruperto, N., Pistorio, A., Ravelli, A., Rider, L. G., Pilkington, C., Oliveira, S., ... Pediatric Rheumatology Collaborative Study Group (PRCSG), R. C. S. G. PRCSG. (2010). The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis care & research, 62(11), 1533-1541.

The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. / Ruperto, Nicolino; Pistorio, Angela; Ravelli, Angelo; Rider, Lisa G.; Pilkington, Clarissa; Oliveira, Sheila; Wulffraat, Nico; Espada, Graciela; Garay, Stella; Cuttica, Ruben; Hofer, Michael; Quartier, Pierre; Melo-Gomes, Jose; Reed, Ann M.; Wierzbowska, Malgorzata; Feldman, Brian M.; Harjacek, Miroslav; Huppertz, Hans Iko; Nielsen, Susan; Flato, Berit; Lahdenne, Pekka; Michels, Harmut; Murray, Kevin J.; Punaro, Lynn; Rennebohm, Robert; Russo, Ricardo; Balogh, Zsolt; Rooney, Madeleine; Pachman, Lauren M.; Wallace, Carol; Hashkes, Philip; Lovell, Daniel J.; Giannini, Edward H.; Gare, Boel Andersson; Martini, Alberto; Paediatric Rheumatology International Trials Organisation (PRINTO), Rheumatology International Trials Organisation (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG), Rheumatology Collaborative Study Group (PRCSG).

In: Arthritis care & research, Vol. 62, No. 11, 11.2010, p. 1533-1541.

Research output: Contribution to journalArticle

Ruperto, N, Pistorio, A, Ravelli, A, Rider, LG, Pilkington, C, Oliveira, S, Wulffraat, N, Espada, G, Garay, S, Cuttica, R, Hofer, M, Quartier, P, Melo-Gomes, J, Reed, AM, Wierzbowska, M, Feldman, BM, Harjacek, M, Huppertz, HI, Nielsen, S, Flato, B, Lahdenne, P, Michels, H, Murray, KJ, Punaro, L, Rennebohm, R, Russo, R, Balogh, Z, Rooney, M, Pachman, LM, Wallace, C, Hashkes, P, Lovell, DJ, Giannini, EH, Gare, BA, Martini, A, Paediatric Rheumatology International Trials Organisation (PRINTO), RITOPRINTO & Pediatric Rheumatology Collaborative Study Group (PRCSG), RCSGPRCSG 2010, 'The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis.', Arthritis care & research, vol. 62, no. 11, pp. 1533-1541.
Ruperto, Nicolino ; Pistorio, Angela ; Ravelli, Angelo ; Rider, Lisa G. ; Pilkington, Clarissa ; Oliveira, Sheila ; Wulffraat, Nico ; Espada, Graciela ; Garay, Stella ; Cuttica, Ruben ; Hofer, Michael ; Quartier, Pierre ; Melo-Gomes, Jose ; Reed, Ann M. ; Wierzbowska, Malgorzata ; Feldman, Brian M. ; Harjacek, Miroslav ; Huppertz, Hans Iko ; Nielsen, Susan ; Flato, Berit ; Lahdenne, Pekka ; Michels, Harmut ; Murray, Kevin J. ; Punaro, Lynn ; Rennebohm, Robert ; Russo, Ricardo ; Balogh, Zsolt ; Rooney, Madeleine ; Pachman, Lauren M. ; Wallace, Carol ; Hashkes, Philip ; Lovell, Daniel J. ; Giannini, Edward H. ; Gare, Boel Andersson ; Martini, Alberto ; Paediatric Rheumatology International Trials Organisation (PRINTO), Rheumatology International Trials Organisation (PRINTO) ; Pediatric Rheumatology Collaborative Study Group (PRCSG), Rheumatology Collaborative Study Group (PRCSG). / The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. In: Arthritis care & research. 2010 ; Vol. 62, No. 11. pp. 1533-1541.
@article{ad061433f9a2484cb35c55530cf310e4,
title = "The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis.",
abstract = "To develop a provisional definition for the evaluation of response to therapy in juvenile dermatomyositis (DM) based on the Paediatric Rheumatology International Trials Organisation juvenile DM core set of variables. Thirty-seven experienced pediatric rheumatologists from 27 countries achieved consensus on 128 difficult patient profiles as clinically improved or not improved using a stepwise approach (patient's rating, statistical analysis, definition selection). Using the physicians' consensus ratings as the {"}gold standard measure,{"} chi-square, sensitivity, specificity, false-positive and-negative rates, area under the receiver operating characteristic curve, and kappa agreement for candidate definitions of improvement were calculated. Definitions with kappa values >0.8 were multiplied by the face validity score to select the top definitions. The top definition of improvement was at least 20{\%} improvement from baseline in 3 of 6 core set variables with no more than 1 of the remaining worsening by more than 30{\%}, which cannot be muscle strength. The second-highest scoring definition was at least 20{\%} improvement from baseline in 3 of 6 core set variables with no more than 2 of the remaining worsening by more than 25{\%}, which cannot be muscle strength (definition P1 selected by the International Myositis Assessment and Clinical Studies group). The third is similar to the second with the maximum amount of worsening set to 30{\%}. This indicates convergent validity of the process. We propose a provisional data-driven definition of improvement that reflects well the consensus rating of experienced clinicians, which incorporates clinically meaningful change in core set variables in a composite end point for the evaluation of global response to therapy in juvenile DM.",
author = "Nicolino Ruperto and Angela Pistorio and Angelo Ravelli and Rider, {Lisa G.} and Clarissa Pilkington and Sheila Oliveira and Nico Wulffraat and Graciela Espada and Stella Garay and Ruben Cuttica and Michael Hofer and Pierre Quartier and Jose Melo-Gomes and Reed, {Ann M.} and Malgorzata Wierzbowska and Feldman, {Brian M.} and Miroslav Harjacek and Huppertz, {Hans Iko} and Susan Nielsen and Berit Flato and Pekka Lahdenne and Harmut Michels and Murray, {Kevin J.} and Lynn Punaro and Robert Rennebohm and Ricardo Russo and Zsolt Balogh and Madeleine Rooney and Pachman, {Lauren M.} and Carol Wallace and Philip Hashkes and Lovell, {Daniel J.} and Giannini, {Edward H.} and Gare, {Boel Andersson} and Alberto Martini and {Paediatric Rheumatology International Trials Organisation (PRINTO)}, {Rheumatology International Trials Organisation (PRINTO)} and {Pediatric Rheumatology Collaborative Study Group (PRCSG)}, {Rheumatology Collaborative Study Group (PRCSG)}",
year = "2010",
month = "11",
language = "English (US)",
volume = "62",
pages = "1533--1541",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "11",

}

TY - JOUR

T1 - The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis.

AU - Ruperto, Nicolino

AU - Pistorio, Angela

AU - Ravelli, Angelo

AU - Rider, Lisa G.

AU - Pilkington, Clarissa

AU - Oliveira, Sheila

AU - Wulffraat, Nico

AU - Espada, Graciela

AU - Garay, Stella

AU - Cuttica, Ruben

AU - Hofer, Michael

AU - Quartier, Pierre

AU - Melo-Gomes, Jose

AU - Reed, Ann M.

AU - Wierzbowska, Malgorzata

AU - Feldman, Brian M.

AU - Harjacek, Miroslav

AU - Huppertz, Hans Iko

AU - Nielsen, Susan

AU - Flato, Berit

AU - Lahdenne, Pekka

AU - Michels, Harmut

AU - Murray, Kevin J.

AU - Punaro, Lynn

AU - Rennebohm, Robert

AU - Russo, Ricardo

AU - Balogh, Zsolt

AU - Rooney, Madeleine

AU - Pachman, Lauren M.

AU - Wallace, Carol

AU - Hashkes, Philip

AU - Lovell, Daniel J.

AU - Giannini, Edward H.

AU - Gare, Boel Andersson

AU - Martini, Alberto

AU - Paediatric Rheumatology International Trials Organisation (PRINTO), Rheumatology International Trials Organisation (PRINTO)

AU - Pediatric Rheumatology Collaborative Study Group (PRCSG), Rheumatology Collaborative Study Group (PRCSG)

PY - 2010/11

Y1 - 2010/11

N2 - To develop a provisional definition for the evaluation of response to therapy in juvenile dermatomyositis (DM) based on the Paediatric Rheumatology International Trials Organisation juvenile DM core set of variables. Thirty-seven experienced pediatric rheumatologists from 27 countries achieved consensus on 128 difficult patient profiles as clinically improved or not improved using a stepwise approach (patient's rating, statistical analysis, definition selection). Using the physicians' consensus ratings as the "gold standard measure," chi-square, sensitivity, specificity, false-positive and-negative rates, area under the receiver operating characteristic curve, and kappa agreement for candidate definitions of improvement were calculated. Definitions with kappa values >0.8 were multiplied by the face validity score to select the top definitions. The top definition of improvement was at least 20% improvement from baseline in 3 of 6 core set variables with no more than 1 of the remaining worsening by more than 30%, which cannot be muscle strength. The second-highest scoring definition was at least 20% improvement from baseline in 3 of 6 core set variables with no more than 2 of the remaining worsening by more than 25%, which cannot be muscle strength (definition P1 selected by the International Myositis Assessment and Clinical Studies group). The third is similar to the second with the maximum amount of worsening set to 30%. This indicates convergent validity of the process. We propose a provisional data-driven definition of improvement that reflects well the consensus rating of experienced clinicians, which incorporates clinically meaningful change in core set variables in a composite end point for the evaluation of global response to therapy in juvenile DM.

AB - To develop a provisional definition for the evaluation of response to therapy in juvenile dermatomyositis (DM) based on the Paediatric Rheumatology International Trials Organisation juvenile DM core set of variables. Thirty-seven experienced pediatric rheumatologists from 27 countries achieved consensus on 128 difficult patient profiles as clinically improved or not improved using a stepwise approach (patient's rating, statistical analysis, definition selection). Using the physicians' consensus ratings as the "gold standard measure," chi-square, sensitivity, specificity, false-positive and-negative rates, area under the receiver operating characteristic curve, and kappa agreement for candidate definitions of improvement were calculated. Definitions with kappa values >0.8 were multiplied by the face validity score to select the top definitions. The top definition of improvement was at least 20% improvement from baseline in 3 of 6 core set variables with no more than 1 of the remaining worsening by more than 30%, which cannot be muscle strength. The second-highest scoring definition was at least 20% improvement from baseline in 3 of 6 core set variables with no more than 2 of the remaining worsening by more than 25%, which cannot be muscle strength (definition P1 selected by the International Myositis Assessment and Clinical Studies group). The third is similar to the second with the maximum amount of worsening set to 30%. This indicates convergent validity of the process. We propose a provisional data-driven definition of improvement that reflects well the consensus rating of experienced clinicians, which incorporates clinically meaningful change in core set variables in a composite end point for the evaluation of global response to therapy in juvenile DM.

UR - http://www.scopus.com/inward/record.url?scp=79952111683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952111683&partnerID=8YFLogxK

M3 - Article

C2 - 20583105

AN - SCOPUS:79952111683

VL - 62

SP - 1533

EP - 1541

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 11

ER -